Inventor
BARF TJEERD
NL22 patents
⚠️ This page may combine multiple inventors who share the name “BARF TJEERD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACERTA PHARMA BV
15 patentsUS10272083B2Apr 30, 2019
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV14 citations93
US9796721B2Oct 24, 2017
Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
ACERTA PHARMA BV12 citations90
US11771696B2Oct 3, 2023
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV5 citations85
US11090302B2Aug 17, 2021
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV4 citations83
US9949971B2Apr 24, 2018
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
ACERTA PHARMA BV11 citations83
US11654143B2May 23, 2023
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
ACERTA PHARMA BV3 citations72
US11166951B2Nov 9, 2021
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor
ACERTA PHARMA BV2 citations72
US10328080B2Jun 25, 2019
Therapeutic combination of PI3K inhibitor and a BTK inhibitor
ACERTA PHARMA BV6 citations72
US10167291B2Jan 1, 2019
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
ACERTA PHARMA BV1 citations71
US12263164B2Apr 1, 2025
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
ACERTA PHARMA BV0 citations62
US11820777B2Nov 21, 2023
Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
ACERTA PHARMA BV0 citations60
US11059829B2Jul 13, 2021
Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
ACERTA PHARMA BV0 citations60
US11110088B2Sep 7, 2021
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
ACERTA PHARMA BV1 citations54
US10736893B2Aug 11, 2020
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
ACERTA PHARMA BV1 citations54
US10640509B2May 5, 2020
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma
ACERTA PHARMA BV0 citations50
BIOVITRUM AB
5 patentsUS7030135B2Apr 18, 2006
Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
BIOVITRUM AB4 citations71
US7125900B2Oct 24, 2006
Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
BIOVITRUM AB1 citations61
US7618961B2Nov 17, 2009
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BIOVITRUM AB1 citations60
US7671051B2Mar 2, 2010
Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
BIOVITRUM AB0 citations50
US7094792B2Aug 22, 2006
Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
BIOVITRUM AB1 citations50